Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7183MR)

This product GTTS-WQ7183MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL), Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ7183MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2122MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ3528MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ4170MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ7884MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ9740MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ6293MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ6552MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ6905MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW